| 摘要 |
FIELD: medicine, pharmacy. ^ SUBSTANCE: invention relates to a transepicutal pharmaceutical composition that contains rotigotin and used in effective treatment of the restless legs syndrome (RLS), especially in form of transdermal therapeutic system based on acrylate or silicon having surface 2.5-20 cm2 and containing rotigotin in the concentration 1.125-9.0 mg/cm2 as an active component against restless less syndrome. The composition improves state of patients suffering from restless legs syndrome as compared with treatment with placebo by 2 units or more according assessment scale of International investigation group of restless legs syndrome (IRLSSG) after administration of the composition for at least 8 days. ^ EFFECT: valuable property and enhanced effectiveness of formulation. ^ 20 cl, 1 tbl, 4 ex |
